Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis

被引：59

作者：

Mathew, Veena ^{[1
]}

Wang, Annabel K. ^{[1
,2
]}

机构：

[1] Univ Calif Irvine, Dept Neurol, UCI ALS & Neuromuscular Ctr, Orange, CA 92668 USA

[2] Tibor Rubin VA Med Ctr, Neurol Sect, Long Beach, CA USA

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2019年 / 13卷

关键词：

antisense oligonucleotide; familial amyloid polyneuropathy; Inotersen; mRNA; RNase H; ANTISENSE OLIGONUCLEOTIDE; LIVER-TRANSPLANTATION; MOLECULAR-MECHANISMS; POLYNEUROPATHY; DIFLUNISAL; THERAPY; GENE;

D O I：

10.2147/DDDT.S162913

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract. Previous treatments using liver transplantation and small molecule stabilizers were not effective in stopping disease progression. Inotersen, a 2'-O-methyoxyethyl-modified antisense oligonucleotide, which acts by reducing the production of transthyretin, was recently demonstrated to improve disease course and quality of life in early hereditary transthyretin amyloidosis polyneuropathy in a 15-month Phase III study.

引用

页码：1515 / 1525

页数：11

共 50 条

[41] Treatment Updates for Neuropathy in Hereditary Transthyretin Amyloidosis
Deandre King
K. H. Vincent Lau
Michelle C. Kaku
Current Treatment Options in Neurology, 2023, 25 : 137 - 149
[42] Hereditary transthyretin amyloidosis
Hund, E.
NERVENARZT, 2014, 85 (10): : 1291 - 1297
[43] Management of Thrombocytopenia in Patients With Hereditary Transthyretin Amyloidosis Treated With Inotersen: Clinical Trial and Postmarketing Surveillance Experience
Gertz, M.
Khella, S.
Wang, A.
Coelho, T.
Waddington Cruz, M.
Polydefkis, M. J.
Plante-Bordeneuve, V.
Berk, J. L.
Barroso, F.
Brannagan, T. H., III
Merlini, G.
Obici, L.
Conceicao, I.
Jung, S. W.
Hughes, S. G.
Aquino, P.
O'dea, L. S. L.
Narayana, A.
Dasgupta, N.
Benson, M. D.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 404 - 405
[44] Monitoring Patisiran and Inotersen Treatment by Quantitative SPECT/CT in Hereditary Transthyretin Amyloid Cardiomyopathy
Rettl, R.
Calabretta, R.
Duca, F.
Binder, C.
Kronberger, C.
Dona, C.
Nitsche, C.
Beitzke, D.
Loewe, C.
Auer-Grumbach, M.
Kastl, S.
Bonderman, D.
Hengstenberg, C.
Eslam, R. Badr
Kastner, J.
Bergler-Klein, J.
Hacker, M.
Kammerlander, A.
WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 : S467 - S468
[45] Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis
Gisela D. Puig-Carrion
Alex Reyentovich
Stuart D. Katz
Clinical Autonomic Research, 2019, 29 : 45 - 53
[46] Treatment characteristics in a cohort of patients with hereditary transthyretin amyloidosis
Qarni, Taha
Bustamante, Nicolas Sarmiento
Jones, Felipe Simoes
Khella, Sami
Drachman, Brian
Pieretti, Janice
Karam, Chafic
NEUROLOGY, 2023, 100 (17)
[47] Current approaches for treatment of hereditary transthyretin amyloidosis (ATTR)
Zibert, Andree
Huesing-Kabar, Anna
Schmidt, Hartmut
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2019, 144 (20) : 1438 - 1443
[48] Diagnosis and treatment of heart failure in hereditary transthyretin amyloidosis
Puig-Carrion, Gisela D.
Reyentovich, Alex
Katz, Stuart D.
CLINICAL AUTONOMIC RESEARCH, 2019, 29 (Suppl 1) : 45 - 53
[49] Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
Yang, Junyi
EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (02) : 95 - 99
[50] MODIFIED NEUROPATHY IMPAIRMENT SCORE+7 COMPONENTS AND LOWER LIMB FUNCTION RESPONSIVENESS IN INOTERSEN TREATMENT OF HEREDITARY TRANSTHYRETIN AMYLOIDOSIS POLYNEUROPATHY
Dyck, P. James
Kincaid, John
Wiessman, Janice
Polydefkis, Michael
Litchy, William
Mauermann, Michelle
Ackermann, Elizabeth
Guthrie, Spencer
Pollock, Michael
Jung, Shiangtung
Baker, Brenda
Dyck, Peter
MUSCLE & NERVE, 2019, 60 : S66 - S66

← 1 2 3 4 5 →